{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:33:30Z","timestamp":1792510410027,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaci.2026.03.026","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:57:23Z","timestamp":1776697043000},"page":"432-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["AZD8630\/AMG 104, an inhaled anti\u2013thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial"],"prefix":"10.1016","volume":"158","author":[{"given":"Sarah R.","family":"Doffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder P.S.","family":"Dosanjh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Waqas","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Asimus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Abuqayyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Cardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane R.","family":"Parnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kovacina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Cushion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Belvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Saralaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor A.","family":"Molfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.03.026_bib2","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.2147\/JIR.S295038","article-title":"Recent insights into the management of inflammation in asthma","volume":"14","author":"Rupani","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jaci.2026.03.026_bib3","article-title":"Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control\u2014a systematic review and meta-analysis","volume":"4","author":"Bignold","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2026.03.026_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105859","article-title":"One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid\u2013long-acting \u03b22-agonist in UK primary care settings","volume":"162","author":"Buhl","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaip.2021.12.027","article-title":"Global variability in administrative approval prescription criteria for biologic therapy in severe asthma","volume":"10","author":"Porsbjerg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.03.026_bib13","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1016\/j.jaip.2021.01.039","article-title":"Lower use of biologics for the treatment of asthma in publicly insured individuals","volume":"9","author":"Akenroye","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.03.026_bib14","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2019.12.009","article-title":"Severe asthma in the US population and eligibility for mAb therapy","volume":"145","author":"Akenroye","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.jaci.2026.03.026_bib15","article-title":"P193 Quantifying the unmet need in severe asthma: an analysis of the number of untreated biologic eligible patients in the UK [abstract]","volume":"77","author":"Dhruve","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2026.03.026_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/all.15609","article-title":"Sounding the alarmins\u2014the role of alarmin cytokines in asthma","volume":"78","author":"Gauvreau","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.03.026_bib17","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/eji.201041195","article-title":"TSLP enhances the function of helper type 2 cells","volume":"41","author":"Kitajima","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2026.03.026_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12026-012-8264-z","article-title":"Functions of thymic stromal lymphopoietin in immunity and disease","volume":"52","author":"Zhang","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaci.2026.03.026_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells12212556","article-title":"Regulatory ILC2\u2014role of IL-10 producing ILC2 in asthma","volume":"12","author":"Emami Fard","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2026.03.026_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01397-2023","article-title":"The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma","volume":"63","author":"Russell","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.03.026_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2222.2008.03151.x","article-title":"Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions","volume":"39","author":"Tanaka","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.03.026_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coi.2020.10.002","article-title":"Mechanisms of non\u2013type 2 asthma","volume":"66","author":"Hudey","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2026.03.026_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/B978-0-12-404717-4.00004-4","article-title":"The biology of thymic stromal lymphopoietin (TSLP)","volume":"66","author":"Ziegler","year":"2013","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.jaci.2026.03.026_bib25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaci.2026.03.026_bib26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2026.03.026_bib27","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib28","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40259-018-0278-1","article-title":"Anticalin\u00ae proteins as therapeutic agents in human diseases","volume":"32","author":"Rothe","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaci.2026.03.026_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.xphs.2020.09.006","article-title":"Contemporary formulation development for inhaled pharmaceuticals","volume":"110","author":"Sou","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jaci.2026.03.026_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","article-title":"Delivery strategies for sustained drug release in the lungs","volume":"75","author":"Loira-Pastoriza","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jaci.2026.03.026_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12325-015-0201-9","article-title":"Asthma control: the right inhaler for the right patient","volume":"32","author":"Scichilone","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2026.03.026_bib33","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1007\/s13346-025-01909-6","article-title":"Inhaled biologics for respiratory diseases: clinical potential and emerging technologies","volume":"15","author":"Shaibie","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.jaci.2026.03.026_bib34","article-title":"Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes","volume":"2018","author":"Borghardt","year":"2018","journal-title":"Can Respir J"},{"key":"10.1016\/j.jaci.2026.03.026_bib35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/17425247.2021.1886074","article-title":"Inhaled fixed-dose combination powders for the treatment of respiratory infections","volume":"18","author":"Brunaugh","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"issue":"suppl","key":"10.1016\/j.jaci.2026.03.026_bib36","volume":"209","author":"Doffman","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib37","article-title":"Pharmacokinetics of AZD8630\/AMG 104 inhaled anti-TSLP in healthy adults and asthma patients [abstract]","volume":"64","author":"Asimus","year":"2024","journal-title":"Eur Respir J"},{"issue":"suppl 68","key":"10.1016\/j.jaci.2026.03.026_bib38","first-page":"OA3652","article-title":"Proof of mechanism for an inhaled anti-TSLP fragment antibody, AZD8630\/AMG104, in a phase 1 study in healthy adults and asthma patients [abstract]","volume":"64","author":"Scott","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.03.026_bib39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/all.16425","article-title":"Early reduction of Feno on anti-IL5 biologics is associated with clinical remission of severe asthma","volume":"80","author":"Soendergaard","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.03.026_bib41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/antiox12020400","article-title":"Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review","volume":"12","author":"Pianigiani","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jaci.2026.03.026_bib42","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/diagnostics13081428","article-title":"Update on the role of FeNO in asthma management","volume":"13","author":"Murugesan","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jaci.2026.03.026_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.957106","article-title":"What is the added value of FeNO as T2 biomarker?","volume":"3","author":"Marcos","year":"2022","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaci.2026.03.026_bib44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib45","doi-asserted-by":"crossref","unstructured":"Korn S, Lanz L, Voigt S, Wilk M, Buhl R. Fractional exhaled nitric oxide is associated with more severe asthma. Eur Respir J 2018;52(suppl 62):PA1099.","DOI":"10.1183\/13993003.congress-2018.PA1099"},{"key":"10.1016\/j.jaci.2026.03.026_bib46","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib47","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2023.11.915","article-title":"Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation","volume":"153","author":"Andreasson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.03.026_bib48","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00560-2023","article-title":"Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey","volume":"9","author":"Crimi","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaci.2026.03.026_bib49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/nop2.399","article-title":"Children\u2019s self-reports of fear and pain levels during needle procedures","volume":"7","author":"Heden","year":"2020","journal-title":"Nurs Open"},{"key":"10.1016\/j.jaci.2026.03.026_bib50","article-title":"Fear of injections and needle phobia among children and adolescents: an overview of psychological, behavioral, and contextual factors","volume":"4","author":"Orenius","year":"2018","journal-title":"SAGE Open Nurs"},{"key":"10.1016\/j.jaci.2026.03.026_bib51","article-title":"A pragmatic guide to choosing biologic therapies in severe asthma","volume":"17","author":"Kavanagh","year":"2021","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.jaci.2026.03.026_bib52","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.xphs.2023.02.010","article-title":"Protein aggregates in inhaled biologics: challenges and considerations","volume":"112","author":"Ibrahim","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jaci.2026.03.026_bib53","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cpt.1694","article-title":"Changes in manufacturing processes of biologic therapies can alter the immunogenicity profile of the product","volume":"107","author":"Vanderlaan","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2026.03.026_bib54","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jaci.2026.03.026_bib55","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.03.026_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.12.085","article-title":"Tezepelumab reduces inflammatory biomarkers as early as week 2 and maintains reductions until week 52 in the phase 3 NAVIGATOR severe asthma trial [abstract]","volume":"149","author":"Griffiths","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.03.026_bib57","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/jcph.1803","article-title":"Pharmacokinetic and pharmacodynamic modeling of tezepelumab to guide phase 3 dose selection for patients with severe asthma","volume":"61","author":"Ly","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926002629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926002629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:18:37Z","timestamp":1785921517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926002629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0091674926002629"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.03.026","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AZD8630\/AMG 104, an inhaled anti\u2013thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}